2025 PARTNERS
The 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe was proud to partner with:
Expertise Partners
Foundation Medicine
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.
Guardant Health
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.
Illumina
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Natera
Natera is a pioneer in molecular disease monitoring, offering a market-leading portfolio of ultra-sensitive assays and real-word data to support clinical development.
Natera’s flagship assay, Signatera™, is a tumor-informed circulating tumor DNA (ctDNA) assay developed for molecular residual disease (MRD) detection, recurrence monitoring, and treatment response monitoring. Signatera™ is supported by 100+ publications across 30+ tumor types and is covered by Medicare for eligible patients with CRC, breast cancer, NSCLC, MIBC, ovarian cancer, and patients receiving IO.
Leveraging its robust commercial footprint, Natera is transforming patient care—40% of U.S. oncologists are ordering, 300K+patients have been tested, and 1.2M+ Signatera™ tests have been ordered to date. Natera brings together technological innovation, a deep commitment to evidence building, and a proven ability to operationalize and commercialize at scale.
Oxford BioDynamics
Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring
ROCHE
With global headquarters located in Basel, Switzerland, Roche is a pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotechnology company and the world leader in vitro diagnostics and tissue-based cancer diagnostics. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche Diagnostics, a division of Roche, offers the industry’s most comprehensive in-vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, laboratory automation and IT and decision support solutions. With its products and services, Roche Diagnostics supports healthcare providers in transforming data into actionable insights.
SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.
Programme Partners
Akoya
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
Almac
Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories.
ANGLE
Over the last six years ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. This creates new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy to assess metastatic breast cancer.
ARC Regulatory
ARC Regulatory is an NI-based specialist regulatory and clinical research organisation, dedicated to supporting companies in the in vitro diagnostic and precision medicine sector. The company’s mission is to be the preferred partner for the global precision medicine and IVD industry, supporting the development of kinder treatments and expediting the highest quality clinical research for improved patient outcomes. In delivering this mission, ARC is proud to have supported more than 50 global biomarker driven drug programmes with the world’s top targeted therapy R&D leaders.
Biocartis
With its revolutionary and proprietary Idylla™ Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla™ Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla™'s continuously expanding menu of molecular diagnostic tests addresses key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain, blood and liver cancer.
For more information, visit www.biocartis.com, or follow Biocartis on Twitter, Facebook or LinkedIn.
Bio-Techne
Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.
Burning Rock Bio
Burning Rock Dx (NASDAQ: BNR) is a global precision oncology leader specializing in NGS-based diagnostics for both tissue and liquid biopsy. With internationally accredited labs (CLIA, CAP, ISO15189, ISO13485) and deep NGS expertise, the company offers a broad portfolio of in-house assays and integrated solutions across the oncology development cycle. Burning Rock supports pharmaceutical development and decentralized clinical implementation, partnering with biopharma and clinical labs to advance trials, biomarker research, and real-world diagnostics. Key milestones include two NMPA-approved IVD kits, four CE-marked assays, and Breakthrough Device Designations from both the FDA and NMPA for its multi-cancer early detection test. Burning Rock is committed to transforming cancer care through innovative, science-driven solutions.
Diagnexia
Diagnexia Analytix offers a world-class pathology network alongside advanced platform-enabled quantitative analytics to empower the next generation of biomarker discovery and companion diagnostics. We deliver bespoke insights tailored for translational and clinical research success - accelerating the journey from discovery to clinical application with precision and efficiency.
Discovery Life Sciences
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
Owkin
Owkin is an AI biotech that unlocks complex biology to find the right treatment for every patient. We use AI to identify new drug candidates, de-risk and accelerate clinical trials, and build diagnostic solutions that improve patient outcomes.
Pillar
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA.
Saga Diagnostics
SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.
Spotlight Partners
Panakeia
Panakeia provides comprehensive ‘omics' molecular analysis of patient tissues significantly faster and cheaper than other methods. We are creating AI technology to provide biomarker information directly from H&E-stained tissue images. Panakeia offers reliable results in minutes rather than executing multiple physical tests over several days or weeks. Our offerings enhance both clinical diagnostics and drug development.
Predicine
Predicine is a Silicon Valley-based molecular insights company dedicated to advancing precision medicine in oncology. We pioneer proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy, enabling minimally invasive molecular diagnostics for treatment selection, therapy response, minimal residual disease (MRD) monitoring, and early cancer detection. Our portfolio includes NGS assays for blood, urine, and tissue, offered through centralized lab testing and decentralized kitted solutions, all designed for globally harmonized use in research, clinical investigation, and companion diagnostic (CDx) development. With operations in Silicon Valley, Houston, Chicago, and Shanghai, Predicine partners with leading biopharma companies, institutions, and governments to support global clinical trials and CDx development. Predicine collaborates with Janssen on liquid biopsy CDx development in bladder cancer.
Panel Partner
Platomics
Platomics automates regulatory processes and connects in vitro diagnostic manufacturers and laboratories to accelerate compliance and bring innovation to patients faster. The PlatoX® platform saves time, resources and costs for all stakeholders involved in IVDR compliance by digitalizing regulatory work on the basis of intelligent data, not docs.
Exhibition Partners
BioIVT
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
Tempus
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
Meeting Partner
Astoriom
At Astoriom, we are the global quality expert in safeguarding R&D sample assets. For over 30 years, our customers have trusted us to secure, protect and preserve their scientific and consumer R&D product samples. We offer a comprehensive portfolio of sample stability storage, biorepository storage, disaster protection & recovery, and sample storage equipment & validation services. Our global environmentally controlled storage solutions enable our customers to safeguard the integrity and viability of their valuable sample assets to advance their research innovation. As a global leader and trusted expert in sample stability and biorepository storage solutions, our team of specialists and engineers offer international regulatory compliant quality processes and custom designed sample storage protocols to the top R&D industries worldwide.
Velsera
Velsera is a global healthcare technology company offering a universal software platform to connect clinical care with discovery. Velsera’s mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec.